Evidence map›Paper›PMID 39670386›Full record

ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2025

A Pathway-Level Information ExtractoR (PLIER) framework to gain mechanistic insights into obesity in Down syndrome.

Sutanu Nandi, Yuehua Zhu, Lucas A Gillenwater, Marc Subirana-Granés, Haoyu Zhang, Negar Janani, Casey Greene, Milton Pividori, Maria Chikina, James C Costello

Abstract read
In one paragraph

Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. PLIERv2: bigger, better and faster.bioRxiv : the preprint server for biology · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sutanu NandiDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Yuehua ZhuDepartment of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA, School of Medicine, Tsinghua University, Beijing, China.
Lucas A GillenwaterDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Marc Subirana-GranésDepartment of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Haoyu ZhangDepartment of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Negar JananiDepartment of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Casey GreeneComputational Bioscience Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Milton PividoriLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, milton.pividori@cuanschutz.edu.
Maria ChikinaDepartment of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA, mchikina@pitt.edu.
James C CostelloDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, james.costello@cuanschutz.edu.

Funding

PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM007635 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI DELL'ACQUA, MARK L · 1985 to 2023
$6.1M
Novel computational strategies to deconvolute co-occurring conditions in Down syndromeR01HD109765 · NICHD · UNIVERSITY OF COLORADO DENVER · PI James Christopher Costello, Casey S Greene · 2022 to 2026
$4.1M
Computational approaches to characterize heterogeneity and improve risk stratification in complex disease phenotypesR00HG011898 · NHGRI · UNIVERSITY OF COLORADO DENVER · PI PIVIDORI, MILTON · 2023 to 2025
$747k
Computational approaches to characterize heterogeneity and improve risk stratification in complex disease phenotypesK99HG011898 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI PIVIDORI, MILTON · 2022 to 2022
$121k
NHGRI NIH HHS K99 HG011898NHGRI NIH HHS R00 HG011898NICHD NIH HHS R01 HD109765NIGMS NIH HHS T32 GM007635
6 · The paper itself

Abstract

Down syndrome (DS), caused by the triplication of chromosome 21 (T21), is a prevalent genetic disorder with a higher incidence of obesity. Traditional approaches have struggled to differentiate T21-specific molecular dysregulation from general obesity-related processes. This study introduces the omni-PLIER framework, combining the Pathway-Level Information ExtractoR (PLIER) with the omnigenic model, to uncover molecular mechanisms underlying obesity in DS. The PLIER framework aligns gene expression data with biological pathways, facilitating the identification of relevant molecular patterns. Using RNA sequencing data from the Human Trisome Project, omni-PLIER identified latent variables (LVs) significantly associated with both T21 and body mass index (BMI). Elastic net regression and causal mediation analysis revealed LVs mediating the effect of karyotype on BMI. Notably, LVs involving glutathione peroxidase-1 (GPX1) and MCL1 apoptosis regulator, BCL2 family members emerged as crucial mediators. These findings provide insights into the molecular interplay between DS and obesity. The omni-PLIER model offers a robust methodological advancement for dissecting complex genetic disorders, with implications for understanding obesity-related processes in both DS and the general population.

Indexed as

Body Mass IndexComputational BiologyDown SyndromeObesityChromosomes, Human, Pair 21HumansMyeloid Cell Leukemia Sequence 1 ProteinMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 Protein

Identifiers

PMID39670386
PMCPMC11649010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.